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1. Key points:
•	 Neurogenic	 inflammation	promotes	 the	 release	of	
cytokines	and	growth	factors,	inducing	extracellular	
matrix	synthesis	by	fibroblasts	in	the	healing	phase.	
Neurogenic	 inflammation	 has	 a	 direct	 modulator	
effect	 on	 the	 subsequent	 phases	 of	 the	 healing	
process,	especially	on	the	proliferative	phase.
•	 Neuropeptides,	 especially	 CGRP	 and	 SP,	
probably	 have	 a	 specific	 and	 active	 participation	
in	 the	 process	 of	 fibrosis,	 and	 directly	 act	 in	 the	
proliferative	phase	of	wound	healing.	
•	 CGRP	 is	 the	most	 abundant	 neuropeptide	 in	 the	
skin,	followed	by	SP,	VIP,	and	other	neuropeptides	
in	smaller	amounts.	
•	 The	aim	of	 this	study	was	 to	 review	 the	action	of	
the	main	neuropeptides,	CGRP	and	SP,	on	cultured	
human	skin	fibroblasts.
•	 VIP	 and	CGRP,	 alone	 or	 in	 combination	with	 SP,	
stimulate	 the	 proliferation	 of	 murine	 and	 human	
keratinocytes;	 however,	 the	 functional	 role	 of	 VIP	
and	CGRP	in	skin	fibroblasts	is	not	well	defined.	
•	 SP	is	one	of	the	most	potent	vasodilators;	it	releases	
nitric	oxide	from	endothelial	cells.	This	effect	is	100	
times	more	potent	than	that	of	histamine	at	similar	
concentrations.	SP	produces	erythema	and	edema	
in	 a	 dose-dependent	 manner,	 but	 unlike	 CGRP,	
it	induces	plasma	extravasation.	
•	 Unlike	 CGRP,	 SP	 induces	 human	 mast	 cell	
degranulation	with	release	of	histamine.
•	 SP	 also	 induces	 proliferation	 of	 human	 dermal	
fibroblasts	 and	 human	 and	 murine	 keratinocytes	
and	 stimulates	 neovascularization	 in vivo and	
proliferation	of	endothelial	and	smooth	muscle	cells.
•	 SP	and	CGRP	are	frequently	present	in	the	same	
nerve	fiber.	SP	release	may	induce	the	co-release	
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of	CGRP,	which	in	turn	may	enhance	the	action	of	
SP,	although	CGRP	may	have	long-lasting	effects.	
The	release	of	SP	or	CGRP	may	induce	an	increase	
in	the	levels	of	SP	receptors.
•	 The	 fact	 that	 human	 skin	 fibroblasts	 express	
neuropeptides	 receptors	 suggests	 that	 they	
may	 respond	 to	 SP	 and	 other	 neuropeptides.	
For	 instance,	 exogenous	 SP	 was	 shown	 to	
induce	autocrine	production	of	SP	by	human	skin	
fibroblasts.
•	 Human	skin	fibroblasts	express	mRNA	for	RAMP1,	
indicating	 that	 these	 cells	 have	 low-expression	 of	
(but	still	express)	CGRP	receptors.
•	 The	ability	of	SP	to	induce	synthesis	and	proliferation	
of	human	dermal	fibroblasts	and	keratinocytes	is	well	
known.	SP	was	shown	to	increase	human	fibroblasts	
proliferation	 in	 a	 concentration-dependent	manner.	
The	 addition	 of	 SP	 to	 cultured	 human	 dermal	
fibroblasts	also	increased	the	motility	of	fibroblasts	in	
a	concentration–dependent	manner.
•	 SP	exerts	 chemoattractant	effects	on	human	skin	
fibroblasts,	 triggering	 a	 concentration-dependent	
migratory	 response,	 and	 NK-1R	 was	 shown	 to	
be	responsible	for	this	effect.		The	ability	of	SP	to	
promote	chemotaxis	in	human	fibroblasts	is	another	
proinflammatory	 activity	 of	 this	 neuropeptide,	
extending	to	the	fibroplasia	phase	of	wound	healing.	
•	 Fibroblasts	and	keratinocytes	can	express	NK-1R	
at	both	protein	and	 transcriptional	 levels,	and	 this	
expression	 is	 upregulated	 by	 SP	 indicating	 that	
these	 cells	 and	 neuropeptide	may	 be	 involved	 in	
the	regulation	of	skin	immune	responses.
•	 Cutaneous	 nociceptive	 nerve	 endings	 are	
needed	 in	 wound	 healing.	 The	 proliferative	
effect	 of	 neuropeptides	 on	 fibroblasts	may	 cause	
disturbances	 of	 wound	 healing,	 which	 may	 be	
associated	 with	 hyperproliferative	 skin	 disorders	
(e.g.,	 keloids)	 and	 mesenchymal	 disorders	
(e.g.,	scleroderma).
•	 The	 understanding	 of	 the	 neuropeptidergic	 action	
on	 fibroblasts	 may	 provide	 relevant	 information	
to	a	deeper	comprehension	of	the	healing	process.	
•	 Despite	 being	 the	 most	 abundant	 neuropeptide	
in	 the	 skin,	 only	 one	 study	 was	 found	 describing	
the	 effects	 of	 CGRP	 in	 combination	 with	 SP	 and	
alpha-MSH	on	cultured	human	skin	fibroblasts	and	
keratinocytes,	 investigating	 the	 IL-8/IL-8R	system.	
The	rationale	was	based	on	the	fact	that	IL-8	plays	an	
important	role	in	cutaneous	inflammation,	and	that	
SP,	CGRP,	and	alpha-MSH	also	regulate	cytokine	
production.	 SP	 and	 CGRP	 in	 concentrations	 of	
10-8M	had	no	effect	on	the	expression	of	IL-8	and	
IL-8R	in	human	dermal	fibroblasts.
•	 Further	 studies	 are	 necessary	 to	 investigate	 the	
action	of	CGRP	on	skin	fibroblasts	and	 its	 role	 in	
the	fibroplasia	phase	of	wound	healing.
2. Introduction
Neurogenic	inflammation	is	caused	by	the	presence	of	
local	neuropeptides,	which	are	special	neurotransmitters	
synthesized	 mainly	 in	 sensory	 neurons	 of	 the	 dorsal	
root	 ganglion	 [1-3]	 and	 released	 by	 exocytosis	 from	
peptidergic	cutaneous	C-fibers	(unmyelinated	afferents	
or	polymodal	C-nociceptors),	and	in	smaller	amounts	by	
thinly	myelinated	A-delta	fibers	[4-6].
Neuropeptides,	 also	 called	 neurotrophins	 or	
neurohormones,	are	released	in	much	smaller	amounts	
than	 common	 small-molecule	 neurotransmitters,	 such	
as	catecholamines.	However,	neuropeptides	are	usually	
1000	times	more	potent	than	neurotransmitters	and	act	
on	their	target	cells	by	paracrine,	juxtacrine	or	endocrine	
signaling	 [7].	While	 common	 neurotransmitters	 act	 as	
a	pool	 in	a	 rapid,	massive	 transient	manner	on	 target	
cells,	the	neuropeptide	action	is	slow	and	has	prolonged	
effects	 that	 may	 last	 for	 days,	 months	 or	 years.	
Therefore,	neuropeptides	promote	long-lasting	changes	
in	the	mechanism	of	cellular	metabolism	by	activating	or	
deactivating	specific	genes	[7].
Calcitonin	gene-related	peptide	(CGRP)	is	the	most	
abundant	 neuropeptide	 in	 the	 skin	 followed	 by	
substance	P	 (SP),	 vasoactive	 intestinal	 peptide	 (VIP),	
and	 other	 neuropeptides	 in	 smaller	 amounts	 [8].	
Usually,	 nerve	 endings	 deep	 in	 the	 dermis	 contain	
increased	quantities	of	CGRP,	SP,	VIP	and	Neurokinin	
A	 (NKA),	 while	 those	 that	 penetrate	 the	 epidermis	
contain	 only	 SP,	 VIP	 and	 NKA	 [9,10].	 The	 cutaneous	
concentration	 of	 neuropeptides	 changes	 according	 to	
the	anatomic	location.	CGRP	is	a	37-amino	acid	peptide	
expressed	by	neurons	and	endocrine	cells	 in	different	
tissues	[11].	 	Two	 isoforms	of	 the	CGRP	peptide	have	
been	 described:	 alpha-CGRP,	 which	 is	 formed	 by	
the	 alternative	 mRNA	 splicing	 of	 the	 calcitonin	 gene	
located	on	chromosome	11;	and	beta-CGRP,	which	 is	
encoded	by	a	different,	but	closely	related	gene	[11-17].	
Alpha-CGRP	 and	 beta-CGRP	 differ	 from	 each	 other	 by	
three	amino	acids	 in	humans	and	by	one	amino	acid	 in	
rats	[13,15],	and	exhibit	overlapping	biological	actions	[16].
CGRP	 acts	 intensively	 on	 sweat	 glands	 and	
perivascular	nerves	[9,18].	The	specific	receptors,	CGRP	
1	and	CGRP	2	receptors,	coupled	to	the	adenylate	cyclase	
system	bind	to	G-proteins	[9].	CGRP	is	the	most	potent	
vasodilator	known	and	its	vasodilator	effect	on	the	skin	
(which	is	constant	in	the	arterioles	of	all	studied	species)	
is	caused	by	direct	action	on	the	muscle	vascular	bed.	
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Therefore,	this	effect	is	independent	of	endothelial	cells	
and	 does	 not	 involve	 protein	 extravasation	 [8,19,20].	
Even	 at	 concentrations	 1000	 times	 that	 needed	 to	
induce	vasodilation,	CGRP	cannot	stimulate	pruritus	or	
pain	in	human	skin.	Also,	CGRP	has	a	limited	or	absent	
capacity	to	release	histamine	from	mast	cells,	although	it	
may	induce	mast	cell	degranulation	and	tumor	necrosis	
factor-alpha	 (TNF-alpha)	 release	 [21].	 On	 the	 other	
hand,	the	trophic	effects	of	CGRP	occur	at	much	lower	
concentrations	than	that	needed	to	induce	vasodilation.	
CGPR	 contributes	 to	 edema	 formation	 induced	 by	
interleukins	 (IL)	1	and	8	 (IL-1	and	 IL-8),	 increases	 the	
expression	 and	 synthesis	 of	 IL-8	 in	 endothelial	 cells,	
is	 a	 chemotactic	 for	 neutrophils	 and	 stimulates	 the	
proliferation	 of	 keratinocytes	 in	mice	 [22].	 CGRP	was	
shown	 to	accelerate	and	 increase	cytokine-dependent	
IL-6	production	in	Swiss	3T3	fibroblast	culture	[23].
SP	 is	 an	 important	 member	 of	 the	 tachykinin	
family.	 It	 is	 an	 11-amino	 acid	 peptide,	 which	 was	
named	 “substance	 P”	 because	 it	 was	 first	 obtained	
as	 a	 “powder”	 [24].	 SP	 and	 NKA	 belong	 to	 the	
phylogenetically	 ancient	 tachykinin	 peptide	 family.	
Tachykinins	 are	 defined	 structurally	 by	 the	 common	
C-terminal	amino	acid	sequence	Phe-Xaa-Gly-Leu-Met-
NH2	(Xaa	=	Phe,	Tyr,	Val,	or	Ile)	[25].	The	mammalian	
tachykinins	 are	 encoded	 on	 three	 different	 genes,	
named	 preprotachykinin	 (TAC)	 1,	 TAC3	 and	 TAC4	
according	to	the	Human	Genome	Organization	(HUGO)	
[26].	TAC1,	the	first	gene	that	was	cloned	from	bovine	
brain,	encodes	SP.	Also,	a	discrete	genomic	segment	of	
TAC1	encodes	NKA	by	alternative	RNA	splicing	of	 the	
same	 gene	 to	 yield	 alpha-TAC1	 and	 beta-TAC1	 [27].	
SP	has	a	similar	distribution	to	CGRP	with	respect	to	its	
targets.	SP	receptors,	neurokinin	(NK)-1R,	NK-2R	and	
NK-3R,	coupled	with	a	G-protein	have	been	described	in	
mast	cells,	polymorphonuclear	 leukocytes,	monocytes,	
macrophages,	 thymus-derived	 (T)	 lymphocytes	
(or	T	cells),	and	bone	marrow-derived	(B)	lymphocytes	
(or	 B	 cells)	 [9,28].	 SP	 is	 one	 of	 the	 most	 potent	
vasodilators;	 it	 releases	 nitric	 oxide	 from	 endothelial	
cells.	 This	 effect	 is	 100	 times	 more	 potent	 than	 that	
of	 histamine	 at	 similar	 concentrations.	 SP	 produces	
erythema	 and	 edema	 in	 a	 dose-dependent	 manner,	
but	unlike	CGRP,	it	induces	plasma	extravasation	[29].	
In	addition,	SP	is	chemotactic	for	T	cells,	enhances	the	
proliferation	 and	 action	 of	 T	 and	 B	 cells,	 induces	 the	
expression	 of	 IL-1	 and	 IL-6	 by	 T	 cells,	 increases	 the	
production	 of	 immunoglobulins,	 the	 activity	 of	 natural	
killer	cells	and	macrophages,	and	the	production	of	IL-1	
and	IL-6	by	T	cells,	TNF-alpha	and	prostaglandin	E	2b	
(PGE	2b)	mediated	by	NK-1R.	However,	unlike	CGRP,	
SP	induces	human	mast	cell	degranulation	with	release	
of	 histamine	 [9,28].	 SP	 also	 induces	 proliferation	 of	
human	dermal	fibroblasts	 [30]	and	human	and	murine	
keratinocytes	[31,32]	and	stimulates	neovascularization	
in vivo and	 proliferation	 of	 endothelial	 and	 smooth	
muscle	 cells	 [9,28,33].	 The	 neuropeptides	 VIP	 and	
CGRP,	 alone	 or	 in	 combination	 with	 SP,	 stimulate	
the	 proliferation	 of	 murine	 [30]	 and	 human	 [34,35]	
keratinocytes;	 however,	 the	 functional	 role	 of	VIP	and	
CGRP	in	skin	fibroblasts	is	not	well	defined	[36].	CGRP	
has	been	shown	to	elicit	3T3	and	IMR-90	(Human	foetal	
lung)	fibroblasts	migration	in	culture,	with	a	chemotactic	
and	chemokinetic	response	[37].
The	 presence	 of	 the	 main	 neuropeptides	 CGRP	
and	SP	in	the	skin,	as	well	as	of	those	others	occurring	
in	 cutaneous	 nerve	 endings,	 is	 directly	 controlled	 by	
the	 availability	 of	 neural	 growth	 factor	 (NGF).	 NGF	 is	
a	 peptide	 synthesized	 and	 secreted	 by	 keratinocytes,	
dermal	 fibroblasts,	 and	 Schwann	 cells	 [38,39].	
The	inverse	also	occurs,	that	is,	neurogenic	inflammation	
or	 the	 presence	 of	 SP	 and	 CGRP	 may	 induce	 an	
increase	in	the	NGF	concentration	in	the	skin,	indicating	
the	existence	of	a	mutual	trophic	communication	whose	
importance	 is	 still	 under	 study,	 especially	 regarding	
tissue	repair	[40].	SP	and	CGRP	are	frequently	present	
in	 the	 same	 nerve	 fiber.	 SP	 release	 may	 induce	 the	
co-release	 of	 CGRP,	 which	 in	 turn	 may	 enhance	
the	 action	 of	 SP,	 although	 CGRP	 may	 have	 long-
lasting	 effects.	Moreover,	 the	 release	 of	SP	 or	CGRP	
may	 induce	an	 increase	 in	 the	 levels	 of	SP	 receptors	
(NK-1R)	[32,41,42].
Since	 1990’s,	 cutaneous	 neurogenic	 inflammation	
has	been	studied	more	extensively	[9].	Sympathetically	
dependent	 neurogenic	 inflammation	 triggers	 a	 strong	
arteriolar	 vasodilation	 effect	 that	 modulates	 the	
amount	of	 inflammatory	mediators	(such	as	histamine,	
arachidonic	 acid,	 bradykinin,	 and	 prostaglandins,	
typical	 of	 the	 inflammatory	 phase	 that	will	 follow)	 and	
the	 global	 recruitment	 of	 immune-inflammatory	 cells,	
which	 together	 activate	 the	 inflammatory	 phase	 of	
wound	 healing	 [1,2,43,44].	 As	 a	 direct	 consequence,	
the	 neurogenic	 inflammation	 promotes	 the	 release	 of	
cytokines	 and	 growth	 factors,	 inducing	 extracellular	
matrix	 synthesis	 by	 fibroblasts	 in	 the	 healing	 phase.	
The	 neurogenic	 inflammation	 has	 a	 direct	modulatory	
effect	on	the	subsequent	phases	of	the	healing	process,	
especially	on	the	proliferative	phase	[45-47].
Neuropeptides,	 especially	 CGRP	 and	 SP,	 have	
a	specific	and	active	participation	in	the	fibrosis	process,	
directly	acting	in	the	proliferative	phase	of	wound	healing	
for	the	production	of	extracellular	matrix	[1,2,4,42].	Dermal	
fibroblasts	 have	 receptors	 for	 these	 neuropeptides,	
but	 their	 role	 in	 these	 cells	 is	 not	 as	 well-known	 as	 in	
the	 neurogenic	 inflammation	 phase.	 The	 expression	 of	
CGRP	 and	 adrenomedullin	 (ADM)	 receptors	 in	 human	
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dermal	fibroblasts	and	keratinocytes	has	been	described,	
but	a	more	profound	analysis	of	the	differentiated	action	of	
these	neuropeptides	in	these	cells	is	yet	to	be	done	[36].	
The	 ability	 of	 SP	 to	 induce	 synthesis	 and	 proliferation	
of	 human	 dermal	 fibroblasts	 and	 keratinocytes	 is	 well	
known	[30,31].	However,	the	fact	that	these	cells	express	
neuropeptides	receptors	suggests	that	they	may	respond	
to	SP	 and	 other	 neuropeptides	 [32].	The	 neuropeptides	
VIP	and	CGRP,	alone	or	in	combination	with	SP,	stimulate	
the	 proliferation	 of	 murine	 [30]	 and	 human	 [34,35]	
keratinocytes,	 but	 the	 functional	 role	 of	 CGRP	 in	 skin	
fibroblasts	is	not	well	defined	[36].	
Cutaneous	 nociceptive	 nerve	 endings	 are	
necessary	 in	wound	healing.	The	proliferative	effect	of	
neuropeptides	 on	 fibroblasts	 may	 cause	 disturbances	
of	 wound	 healing,	 which	 may	 be	 associated	 with	
hyperproliferative	 skin	 disorders	 (e.g.,	 keloids)	 and	
mesenchymal	disorders	(e.g.,	scleroderma)	[36,48,49].	
The	 understanding	 of	 the	 neuropeptidergic	 action	 on	
fibroblasts	may	provide	relevant	information	to	a	deeper	
comprehension	 of	 the	 healing	 process.	 The	 subject	
of	 our	 study,	 neuropeptides	 in	 experimental	 in vitro	
studies,	wouldn’t	allow	a	proper	systematic	review	due	
to	the	intrinsic	nature	of	the	articles	and	of	the	subject	
itself.	 However,	 a	 review	 using	 a	 systematization	 of	
the	 literature	 search	 strategy	 could	 bring	 significant	
contribution	 to	 the	 understanding	 of	 the	 action	 of	 the	
major	neuropeptides	in	the	proliferative	phase	of	wound	
healing,	 after	 the	 neurogenic	 inflammation	 phase.	
Besides	that,	this	search	strategy	systematization	allows	
the	review	to	include	all	articles	exclusively	relevant	to	
the	subject	and,	since	the	search	strategy	is	presented,	
it	 also	 allows	 the	 review	 to	 be	 updated	 at	 any	 time.	
Therefore,	the	aim	of	this	study	was	to	review	the	action	
of	the	main	neuropeptides,	CGRP	and	SP,	on	cultured	
human	skin	fibroblasts.	
3. Methods
A	 systematic	 literature	 search	 was	 conducted	 on	
Medline	 (PubMed)	 and	 Web	 of	 Science	 (Thomson	
Reuters)	databases	on	December	21,	2013.	The	search	
strategies	were	as	follows:
(a)	PubMed	–	search	1:
Search	 (“Calcitonin	 Gene-Related	 Peptide”[Mesh]	 OR	
“Substance	 P”[Mesh])	 AND	 “Fibroblasts”[Mesh]	 AND	
“Skin”[Mesh]	AND	“Cells,	Cultured”[Mesh]
(b)	PubMed	–	search	2:
Search	 (“Calcitonin	 Gene-Related	 Peptide”	 OR	
“Substance	 P”)	 AND	 “Fibroblasts”	 AND	 “Skin”	 AND	
“Cells,	Cultured”
(c)	Web	of	Science:
TS=	(Fibroblast*	AND	(Calcitonin-Gene	Related	Peptide	
OR	Substance	P)	AND	(Skin)	AND	(Cultured	Cell*))
No	 qualifier	 or	 limit	 was	 used	 in	 the	 search.	
Publications	found	simultaneously	in	both	databases	
were	counted	only	once.	The	articles	were	categorized	
according	 to	 the	 model	 used	 (human	 or	 animal),	
and	 neuropeptide(s)	 studied.	 For	 the	 selected	
articles,	 we	 also	 checked	 the	 References	 section	
as	 some	 important	 articles	 couldn’t	 be	 retrieved	 by	
the	 search	 criteria.	 The	 conclusions	 of	 the	 studies	
were	summarized	and	review	articles	were	excluded	
from	the	study.	Articles	in	which	the	content	was	not	
related	 to	 the	 objectives	 of	 the	 present	 study	 were	
also	excluded.
4. Results
A	 total	 of	 74	 articles	 were	 retrieved	 using	 the	
proposed	search	strategies	of	which	14	articles	were	
retrieved	 from	Medline	 (PubMed	 search	 1),	 21	 from	
Medline	(PubMed	search	2)	with	a	total	of	24	different	
articles	 from	 both	 Pubmed	 searches	 (1	 and	 2),	
and	 50	 articles	 retrieved	 from	 Web	 of	 Science.	
However,	13	articles	were	common	to	both	databases,	
so	 that	 61	 different	 articles	 were	 retrieved.	 Also,	 5	
review	articles	 and	46	 articles	 presenting	 topics	 not	
related	to	the	objectives	of	 this	study	were	excluded	
from	 the	 sample.	 Ten	 articles	 were	 previously	
selected	using	the	search	engines,	which	studied	the	
action	of	the	main	neuropeptides	on	cultured	human	
skin	fibroblasts.	For	these	articles	(and	for	all	articles	
selected	thereafter),	we	also	checked	the	References	
section,	 as	 some	 relevant	 articles	 seemed	 to	 have	
escaped	the	search	criteria.	Three	new	articles	were	
retrieved	this	way,	for	a	total	of	13	articles	concerning	
the	 action	 of	 CGRP	 and/or	 SP	 on	 cultured	 human	
skin	fibroblasts,	of	which	12	were	 related	 to	SP	and	
1	 was	 related	 to	 both	 CGRP	 and	 SP.	 A	 summary	
of	 the	 content	 of	 these	 articles	 is	 shown	 in	 Table	 1
[30,50-61].	A	schematic	drawing	is	proposed	showing	
the	molecular	mechanisms	of	CGRP	and	SP	in	human	
skin	fibroblasts	and	is	shown	in	Figure	1.
5. Discussion
A	study	has	 investigated	the	effects	of	CGRP,	SP	and	
alpha-melanocyte-stimulating	 hormone	 (alpha-MSH)	
on	the	IL-8/IL-8R	system	in	a	cultured	human	keratinocyte	
cell	 line	and	dermal	fibroblasts	[50].	The	rationale	was	
based	on	the	fact	that	IL-8	plays	an	important	role	in	the	
cutaneous	inflammation	and	SP,	CGRP,	and	alpha-MSH	
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also	regulate	cytokine	production.	The	authors	reported	
that	alpha-MSH	 induced	a	 time-dependent	expression	
of	 IL-8	 mRNA	 in	 fibroblasts,	 while	 SP	 and	 CGRP	
did	 not	 act	 on	 dermal	 fibroblasts	 at	 a	 concentration	
of	10-8	M	L-1.	On	the	other	hand,	SP	and	CGRP	upregulated	
the	expression	of	IL-8	mRNA	in	keratinocytes,	but	had	
no	effect	on	the	production	of	IL-8;	alpha-MSH	had	no	
effect	on	either	IL-8	or	IL-8/IL-8R	system	in	these	cells	
[50].
Neuropeptides	 exert	 a	 variety	 of	 modulatory	
effects	 on	 inflammatory	 cellular	 responses.	 In	 order	
to	 investigate	 other	 activities	 of	 neuropeptides	 in	 the	
inflammatory	 processes,	 a	 study	 has	 assessed	 the	
ability	of	SP	to	stimulate	chemotaxis	in	human	fibroblasts	
[51].	 Kähler	et al.	 [52]	 reported	 that	 SP	was	 a	 potent	
chemoattractant	for	human	fibroblasts	in vitro,	triggering	
a	 concentration-dependent	migratory	 response.	When	
testing	the	chemoattractant	properties	of	SP	fragments,	
only	the	C-terminal	fragment	analog	induced	migratory	
responses	 [52].	 It	 was	 suggested	 that	 chemotactic	
responsiveness	 is	 encoded	 by	 the	 C-terminus	 of	
the	SP,	which	 is	 known	 to	 be	 active	 in	NK	 receptors.	
The	 ability	 of	 substance	 P	 to	 promote	 chemotaxis	 in	
human	 fibroblasts,	 which	 extends	 to	 the	 fibroplasia	
phase	 of	 wound	 healing,	 is	 another	 proinflammatory	
activity	of	this	neuropeptide	[52].
Other	 study	 has	 addressed	 cell	migration	 and	 the	
distance	 human	 dermal	 fibroblasts	 move	 after	 the	
addition	of	SP	to	the	culture	medium	[53].	The	authors	
observed	 an	 increase	 in	 the	 motility	 of	 fibroblasts	
Retrived Articles Neuropeptides Action on skin fibroblasts
1 Nilsson et al., 1985 [30] SP SP stimulate DNA synthesis in cultured human skin fibroblasts, and this stimulation is inhibited by the SP-antagonist spantide.
2 Kiss et al., 1999 [50] CGRP and  SP SP and CGRP in concentrations of 10
-8 M had no effect on the expression of Interleukin 8 (IL-8) 
and Interleukin 8 Receptor (IL-8R) in human dermal fibroblasts.
3 Kähler et al., 1993 [51] SP
SP potently stimulated fibroblast growth in the presence of acetylsalicylic acid after growth arrest 
by 48 h serum starvation.
SP stimulated fibroblast growth in a manner typical of competence factors.
Arachidonic acid metabolites were involved in the cell cycle-dependent mitogenic action of SP 
on human skin fibroblasts.
4 Kähler et al., 1993 [52] SP SP had a potent chemotactic effect, attracting human dermal fibroblasts in a concentration-dependent manner.
5 Parenti et al., 1996 [53] SP The addition of SP to cultured human dermal fibroblasts increased the motility of fibroblasts in a concentration–dependent manner with a 50%  increase in migration at a concentration of 10-8 M.
6 Bae et al., 2002 [54] SP Exogenous SP induced autocrine production of SP by human skin fibroblasts.
7 Liu et al., 2006 [55] SP
SP and gamma interferon (IFN-gamma) upregulated the expression of Neurokinin 1 Receptor 
(NK-1R) in human dermal fibroblasts, as well as in HaCaT (a human epidermal keratinocyte cell 
line) cells.
8 Kähler et al., 1996 [56] SP The combination of SP with Epidermal Growth Factor (EGF) synergistically stimulated the proliferation of human dermal fibroblasts and release of PGE 2.
9 Hu et al., 2002 [57] SP SP increased the proliferation of human fibroblasts in a concentration-dependent manner.
10 Morbidelli et al., 1993 [58] SP
Synthetic selective NK-1R antagonists of human skin fibroblasts induced a significant 
displacement to the right of the dose-response curves induced by SP and the selective NK-1R 
agonist.
The selective NK-2R antagonist did not modify the proliferative response to the tachykinins used.
The growth-promoting effect of Basic Fibroblast Growth Factor (bFGF) was not changed by any 
of the tachykinin antagonists tested. 
11 Xie et al., 2011 [59] SP
Fibroblastic CD10 expression may down-regulate skin inflammation by degrading SP or 
reducing its level in the dermal microenvironment.
Targeted disruption of CD10 by siRNA augmented SP production from Fbs
12 Liu et al., 2007 [60] SP
SP induced the production of IFN-gamma, IL-1beta, IL-8 and Monocyte Chemotactic Protein 
(MCP)-1 in HaCaT cells and human dermal fibroblasts. 
Matrine 5-100 µg/mL inhibited SP-induced IL-1beta, IL-8 and (MCP)-1 production in HaCaT cells 
and human dermal fibroblasts, with no effect on IFN-gamma production in both cells. 
SP had no effect on IL-6 secretion in HaCaT cells and human dermal fibroblasts.
Fibroblasts did not constitutively secrete Tumor Necrosis Factor-gamma (TNF-gamma). Neither 
SP nor matrine induced the secretion of this cytokine.
13 Liu et al., 2008 [61] SP
SP induced the production of IFN-gamma, IL-1beta and IL-8 in HaCaT cells and human dermal 
fibroblasts. 
Cetirizine 1-100 micromol x L(-1) inhibited SP-induced IL-1beta and IL-8 production in HaCaT 
cells and human dermal fibroblasts, with no effect on IFN-gamma production in both cells. 
SP had no effect on IL-6 secretion in HaCaT cells and human dermal fibroblasts.
Table 1. Summary of the action of the neuropeptides CGRP and SP on skin fibroblasts.
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in	 a	 concentration-dependent	 manner.	 An	 SP	
concentration	 of	 10-8	 M	 lead	 to	 a	 50%	 increase	 in	
fibroblast	migration.	SP	is	a	potent	effector	of	fibroblast	
migration,	 and	 NK-1R	 is	 responsible	 for	 this	 effect.	
These	 observations	 reinforce	 the	 importance	 of	 the	
specific	role	of	NK-1R	in	mediating	the	trophic	function	
of	SP	at	the	level	of	skin	fibroblasts	[53].	
Neutral	 endopeptidase	 (NEP)	 is	 a	 cell-surface	
enzyme	 that	 degrades	 SP.	 NEP	mRNA	was	 detected	
in	 fibroblasts,	 keratinocytes	 and	 endothelial	 cells	 in	
the	 skin	and	wound	 tissue,	which	makes	 this	enzyme	
a	possible	 factor	 in	 the	attenuation	of	proinflammatory	
and	mitogenic	action	of	these	neuropeptides	[62].	
A	 study	 on	 the	 mechanisms	 that	 regulate	 the	
autocrine	induction	of	SP	by	cultured	human	fibroblasts	
has	shown	for	the	first	time	that	SP	mRNA,	NEP	mRNA,	
and	SP	may	 be	 induced	 by	 normal	 skin	 fibroblasts	 in	
response	to	exogenous	SP	[54].	
SP	can	be	a	possible	factor	in	the	pathogenesis	of	
cutaneous	allergic	inflammation.	An	investigation	of	the	
expression	of	NK-1R	for	SP	in	cultured	human	dermal	
fibroblasts	 and	 epidermal	 keratinocytes	 has	 reported	
that	 fibroblasts	 and	 keratinocytes	 can	 express	NK-1R	
at	both	protein	and	 transcriptional	 levels,	and	 that	 this	
expression	 is	 upregulated	 by	 SP,	 gamma-interferon	
(IFN-gamma)	 and	 spantide	 I	 [55].	 This	 suggests	 that	
fibroblasts	 and	 keratinocytes	 may	 be	 involved	 in	
the	 regulation	 of	 skin	 immune	 responses,	 and	 that	
NK-1R	may	play	an	important	role	in	the	pathogenesis	
of	cutaneous	allergic	inflammation	[55].
SP	stimulates	the	growth	and	proliferation	of	human	
dermal	fibroblasts	through	arachidonic	acid	metabolites.	
Other	investigations	have	reported	that	when	cell	growth	
was	interrupted	due	to	serum	deprivation	for	more	than	
48	h,	SP	was	not	able	to	stimulate	fibroblast	proliferation	
[51].	SP,	fibroblast	growth	 factor	 (FGF)	and	epidermal	
Figure 1.  Schematic drawing showing the molecular mechanisms of CGRP and SP in human skin fibroblasts. Fb: Fibroblast; SP: Substance 
P; CGRP: Calcitonin Gene-Related Peptide; CD10: Cluster of Differentiation 10; EGF : Epidermal Growth Factor ; IL-1beta: Interleukin 
1 beta; IL-6: Interleukin 6; IL-8: Interleukin 8; IL-8R: Interleukin 8 Receptor; IFN-gamma: Gamma Interferon; (MCP)-1: Monocyte 
Chemotactic Protein 1; PGE: Prostaglandin E; TNF-gamma: Tumor Necrosis Factor-gamma; NK-1 R: Neurokinin 1 Receptor (SP 
Receptor); CLR : Calcitonin-Like Receptor; RAMP1: Receptor-Activity-Modifying Protein 1; RCP : Receptor Component Protein. Blue 
arrows: no effect. Red arrows: possible effect. 
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growth	 factor	 (EGF)	 are	 mitogenic	 for	 fibroblasts	
[51].	 Another	 investigation	 has	 tested	 the	 effects	
of	a	submaximal	concentration	of	SP	(10-9	M)	combined	
with	 either	 FGF	 or	 EGF	 on	 fibroblast	 proliferation	
and	 release	 of	 arachidonic	 acid	 metabolites.	 The	
authors	observed	that	the	combination	of	SP	with	EGF	
synergistically	stimulated	the	proliferation	of	fibroblasts	
and	 release	 of	 PGE	 2,	 while	 the	 addition	 of	 SP	 to	
cultures	 containing	FGF	had	no	effect	 on	 cell	 growth.	
Therefore,	 the	 interactions	 of	 SP	 with	 FGF	 and	 EGF	
differently	affect	 the	mitogenic	 response	based	on	 the	
release	of	arachidonic	acid	metabolites	[56].
SP	 also	 affects	 the	 proliferation	 of	 skin	 fibroblasts	
[52].	 A	 study	 on	 the	 role	 of	 SP	 in	 the	 formation	 of	
hypertrophic	 scars	 has	 reported	 that	 SP	 increased	
in vitro	 proliferation	 of	 skin	 fibroblasts	 in	 a	 dose-
dependent	 manner,	 with	 maximum	 rate	 for	 an	 SP	
concentration	of	25	ng	mL-1	 [58].	Moreover,	after	48	h	
in	 culture	with	SP	 (25	 ng	mL-1),	 fibroblasts	 expressed	
more	mRNA	for	transforming	growth	factor	(TGF)-beta	
1	than	those	that	were	not	exposed	to	the	neuropeptide,	
suggesting	 that	 SP	may	 play	 an	 important	 role	 in	 the	
phenotypic	 changes	of	 fibroblasts	during	skin	healing.	
A	disturbance	in	the	expression	of	these	changes	may	
result	in	the	formation	of	hypertrophic	scars	and	possibly	
keloids	[57].		
The	 effects	 of	 synthetic	 selective	 tachykinin	
receptor	 antagonists	 on	 the	 growth	 of	 cultured	 human	
skin	 fibroblasts	 have	 been	 evaluated	 [58].	 Selective	
antagonists	for	the	NK-1R	and	NK-2R	were	tested	against	
SP,	against	a	selective	NK-1R	agonist,	and	against	basic	
fibroblast	 growth	 factor	 (bFGF).	 All	 selective	 NK-1R	
antagonists	 tested	 at	 the	 concentration	 of	 10-5	 M	 L-1
induced	 a	 significant	 displacement	 to	 the	 right	 of	 the	
dose-response	curves	induced	by	SP	and	by	the	selective	
NK-1R	agonist.	The	selective	NK-2R	antagonist	did	not	
change	the	proliferative	response	to	the	tachykinins	used.	
The	growth-promoting	effect	of	bFGF	was	not	affected	by	
any	of	the	antagonists	tested.	These	results	indicate	that	
the	synthetic	receptor-selective	antagonists	may	become	
an	important	tool	to	the	study	of	in vitro	biological	effects	
of	tachykinin	on	cultured	cells	[58].	
CGRP	 and	 ADM	 couple	 to	 the	 same	 type	 of	
transmembrane	 receptor,	 the	 calcitonin-like	 receptor	
(CLR).	 The	 selective	 specificity	 of	 CLR	 for	 these	
peptides	 depends	 on	 which	 members	 of	 a	 family	
of	 single-transmembrane-domain	 proteins,	 called	
receptor-activity-modifying	 proteins	 (RAMPs),	 are	
expressed	(i.e.,	RAMP1,	RAMP2	or	RAMP3)	[63].	The	
simultaneous	expression	of	CLR	and	RAMP	is	essential	
for	 the	 expression	 of	 functional	 receptors.	 Studies	 on	
transfection	of	 different	 cell	 types	have	 confirmed	 this	
hypothesis	[63-65].	
COS-7	 fibroblasts	 (African	 green	 monkey	 kidney	
COS-7	 cells)	 do	 not	 express	 significant	 levels	 of	
endogenous	 RAMPs	 [66],	 but	 have	 been	 commonly	
used	as	a	transfection	model.	Transfection	of	rat	CLR,	
when	 co-expressed	 with	 mRAMP1	 in	 COS-7	 cells,	
results	in	the	expression	of	a	functional	CGRP	receptor	
[64].	
The	 rat	 myogenic	 cell	 line	 L6	 is	 considered	 a	
fibroblast	 cell	 line	 and	 has	 receptors	 for	 CGRP	 in	 its	
endogenous	form.	The	cell	line	L6	expresses	mRNA	for	
RAMP1	and	RAMP2;	Rat-2	fibroblasts	express	mRNA	
only	for	RAMP2	[67]	without	receptor	for	CGRP.	Withers	
et al.	 [67]	 reported	 that	 Swiss	 3T3	 fibroblasts	 have	
high-affinity	receptors	for	ADM,	but	no	CGRP	receptor.	
On	the	other	hand,	Evans	et al.	[69]	detected	functional	
CGRP	receptors	by	cAMP	assays	in	NIH3T3	cells.
Human	skin	fibroblasts	express	mRNA	for	RAMP1,	
indicating	 that	 human	 skin	 fibroblasts	 have	 low-
expression	of	(but	still	express)	CGRP	receptor	[36].	
Evans	et al.	 [69],	working	with	NIH3T3	and	COS-7	
fibroblasts,	 proposed	 that	 a	 functional	CGRP	 receptor	
complex	 requires	 at	 least	 three	 proteins:	 the	 CGRP	
receptor	 itself,	 composed	 by	 CLR	 and	 RAMP1	 (the	
chaperone	 protein	 to	 route	 CLR	 to	 the	 cell	 surface),	
and	 a	 receptor	 component	 protein	 (RCP)	 to	 couple	
the	 complex	 CLR	 +	 RAMP1	 to	 the	 cellular	 signal	
transduction	pathway.
In	conclusion,	although	CGRP	is	the	most	abundant	
neuropeptide	 in	 the	 skin,	 only	 one	 study	 was	 found	
in	 the	 literature	 describing	 the	 action	 of	 CGRP	 in	
combination	with	SP	on	cultured	human	skin	fibroblasts.	
SP	 is	 a	 neuropeptide	 that	 has	 been	 shown	 to	 exert	
proliferative	 and	 chemoattractant	 effects	 on	 human	
skin	fibroblasts,	and	 to	be	 linked	 to	cutaneous	 immune	
reactions.	Human	skin	fibroblasts	have	low-expression	of	
CGRP	receptor.	Therefore,	further	studies	are	necessary	
to	investigate	the	action	of	CGRP	on	skin	fibroblasts	and	
its	role	in	the	fibroplasia	phase	of	wound	healing.
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